The sensation may be most pronounced following meals or during dose escalation periods, and some patients find that eating smaller, more frequent meals helps minimize this discomfort
2022A1515110720 & 2023B1212060063)
The New England Journal Of Medicine 2026 PMID: 42253238, DOI: 10.1056/nejmoa2600751.Peer-Reviewed Original ResearchCitationsAltmetricConceptsGlucagon-like peptide-1Dose escalation periodPlacebo groupEarly discontinuationBody weightTreatment of adultsDouble-blind trialPhase 2 trialBaseline to weekObesity-related complicationsManagement of obesityObesity medicationsBody-mass indexMean BMIPlaceboEfficacy analysisNo deathsAdverse eventsCardiometabolic benefitsMean body weightGastrointestinal symptomsLifestyle modificationParticipantsEnd pointsAdults Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial Rosenstock J, Lingvay I, Ryan D, Jastreboff A , Kushner R, Acosta A, Blevins T, Choi M, Holmes F, Smith T, Connery L, Li Y, Liu M, Barth A, Butcher J, Civitarese A, Yue H, Coll B

This flexibility in administration routes offers practical advantages for addressing injuries in different body locations